Evogene to Present Innovative Approach for Improving Cannabis for Medical Needs at CannaTech Summit
March 07 2017 - 6:00AM
Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading company for the
improvement of crop productivity and economics for food, feed and
fuel, announced today that Mr. Yuval Ben-Galim, Evogene's COO, will
present at the CannaTech 2017 annual cannabis summit, taking place
in Tel-Aviv, Israel on March 21st. The summit will focus on
acceleration of cannabis innovation, with wide spectrum of global
industry leaders spanning from science to government.
Cannabis is now being widely acknowledged for
its potential to facilitate medicinal benefits. One of the major
limitations in the field is developing various stable cannabis
strains that contain the desired active components that meet
precise medicinal needs for different diseases and indications. As
we recently disclosed, cannabis is one of the crops Evogene is
evaluating for the extension of its program focus. At the
conference, Mr. Ben-Galim will present Evogene's approach, which
utilizes the Company’s predictive biology technology platform to
develop innovative cannabis strains that are specifically generated
for medicinal requirements, to potentially address this
challenge.
About Evogene Ltd.:Evogene
(NASDAQ:EVGN) (TASE:EVGN) is a leading biotechnology company for
the improvement of crop productivity for the food, feed and fuel
industries. The Company operates in three key target markets:
improved seed traits (addressing yield increase, tolerance to
environmental stresses and resistance to insects and diseases);
innovative ag-chemicals (developing novel herbicide solutions for
weed control); and ag-biologicals. Evogene has collaborations with
world-leading seed and ag-chemical companies. For more information,
please visit www.evogene.com or contact the Company
at info@evogene.com.
This press release contains "forward-looking
statements" relating to future events. These statements
may be identified by words such as "may", "could",
“expects”, "intends", “anticipates”,
“plans”, “believes”, “scheduled”, “estimates” or words of
similar meaning. Such statements are based on current
expectations, estimates, projections and assumptions,
describe opinions about future events, involve certain
risks and uncertainties which are difficult to predict and are
not guarantees of future performance. Therefore, actual future
results, performance or achievements of Evogene may differ
materially from what is expressed or implied
by such forward-looking statements due to a variety of
factors, many of which beyond Evogene's
control, including, without limitation, those risk
factors contained in Evogene’s reports filed with the
appropriate securities authority. Evogene disclaims any
obligation or commitment to update these forward-looking statements
to reflect future events or developments or changes in
expectations, estimates, projections and assumptions.
Evogene (NASDAQ:EVGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Evogene (NASDAQ:EVGN)
Historical Stock Chart
From Sep 2023 to Sep 2024